{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:24:40Z","timestamp":1789680280578,"version":"4.0.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug-resistant epilepsy (DRE), characterized by seizures that are unresponsive to the use of two or more conventional anti-seizure medication (ASMs), poses a significant therapeutic challenge. In recent years, cannabidiol (CBD), a non-psychoactive compound derived from <jats:italic>Cannabis sativa<\/jats:italic>, has emerged as a promising adjunctive therapy for specific, severe epilepsy syndromes. The approval of a highly purified 99% CBD oral solution (Epidiolex<jats:sup>\u00ae<\/jats:sup>) has facilitated its integration into clinical practice. However, its effective and safe use requires a nuanced understanding of several practical considerations. This narrative review synthesizes current evidence on the practical aspects of prescribing and administering highly purified CBD oral solution in patients with drug-resistant epilepsy (DRE). I address evidence-based dosing strategies, relevant drug-drug interactions, the profile of adverse-drug reactions (ADRs) and their management, and the critical importance of gradual dose titration. A comprehensive literature search was conducted to identify relevant clinical trials, systematic reviews, observational studies, real-world evidence, and other pertinent publications. A \u201cstart low, go slow\u201d dosing approach is essential to mitigate ADRs, which are generally mild to moderate but may include somnolence, decreased appetite, diarrhea, and, most notably, elevated liver transaminases, particularly with concurrent valproate use. Significant pharmacokinetic interactions, especially with clobazam, require careful monitoring and potential dose adjustments of concomitant ASMs. This review offers a consolidated overview of the practical considerations for CBD therapy, aiming to support clinicians in optimizing treatment outcomes for patients with DRE while ensuring patient safety.<\/jats:p>","DOI":"10.3389\/fphar.2025.1681815","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:12:18Z","timestamp":1756959138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review"],"prefix":"10.3389","volume":"16","author":[{"given":"Cristian E.","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3390\/nu14102152","article-title":"Cannabidiol and cannabidiol metabolites: pharmacokinetics, interaction with food, and influence on liver function","volume":"14","author":"Abbotts","year":"2022","journal-title":"Nutrients"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101074","DOI":"10.1016\/j.vhri.2024.101074","article-title":"Cost analysis of epilepsy healthcare in adults: a direct cost estimate from a Colombian perspective","volume":"47","author":"Alegr\u00eda-Mu\u00f1oz","year":"2025","journal-title":"Value Health Reg. Issues"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1684\/epd.2020.1141","article-title":"Epilepsy and cannabidiol: a guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.seizure.2021.11.020","article-title":"High dose cannabidiol (CBD) in the treatment of new-onset refractory status epilepticus (NORSE)","volume":"94","author":"Aydemir","year":"2022","journal-title":"Seizure"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.neubiorev.2020.09.027","article-title":"Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy","volume":"132","author":"Boleti","year":"2022","journal-title":"Neurosci. Biobehav Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2022.01.001","article-title":"Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy","volume":"95","author":"Caraballo","year":"2022","journal-title":"Seizure"},{"key":"B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.15446\/revfacmed.v63n3.47460","article-title":"Cannabis sint\u00e9tico: aspectos toxicol\u00f3gicos, usos cl\u00ednicos y droga de dise\u00f1o","volume":"63","author":"Casadiego Mesa","year":"2015","journal-title":"Rev. la Fac. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome","volume":"378","author":"Devinsky","year":"","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (epidiolex\u00ae) in patients with CDKL5 deficiency disorder and aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"","journal-title":"Epilepsy and Behav."},{"key":"B13","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2017.08.010","article-title":"Physicians-in-training are not prepared to prescribe medical marijuana","volume":"180","author":"Evanoff","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","article-title":"Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"10","author":"Feigin","year":"2025","journal-title":"Lancet Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s10072-020-04514-2","article-title":"Current application of cannabidiol (CBD) in the management and treatment of neurological disorders","volume":"41","author":"Fiani","year":"2020","journal-title":"Neurol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000539754","article-title":"Long-term treatment for unspecified anxiety disorders with cannabidiol (CBD): a retrospective case series from real-world evidence (RWE) in Colombia","author":"Galvez-Florez","year":"2024","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107862","DOI":"10.1016\/j.yebeh.2021.107862","article-title":"Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy","volume":"117","author":"Gaston","year":"2021","journal-title":"Epilepsy and Behav."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"108190","DOI":"10.1016\/j.yebeh.2021.108190","article-title":"Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy","volume":"122","author":"Grayson","year":"2021","journal-title":"Epilepsy and Behav."},{"key":"B24","doi-asserted-by":"publisher","first-page":"108558","DOI":"10.1016\/j.yebeh.2022.108558","article-title":"Electroencephalographic changes in purified pharmaceutical cannabidiol therapy","volume":"128","author":"Herlopian","year":"2022","journal-title":"Epilepsy and Behav."},{"key":"B25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/practneurol-2018-002137","article-title":"Cannabis and multiple sclerosis","volume":"19","author":"Ingram","year":"2019","journal-title":"Pract. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/epi4.12411","article-title":"Add\u2010on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy","volume":"5","author":"Kuchenbuch","year":"2020","journal-title":"Epilepsia Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real\u2010world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study","volume":"8","author":"K\u00fchne","year":"2023","journal-title":"Epilepsia Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2009","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1684\/epd.2019.1123","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Landmark","year":"2020","journal-title":"Epileptic Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and lennox-gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur. J. Intern Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/ph14070630","article-title":"UHPLC-MS\/MS analysis of cannabidiol and its metabolites in serum of patients with resistant epilepsy treated with CBD formulations","volume":"14","author":"Malaca","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/can.2019.0082","article-title":"An open retrospective study of a standardized cannabidiol based-oil in treatment-resistant epilepsy","volume":"7","author":"Marchese","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1111\/epi.16596","article-title":"Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid","volume":"61","author":"McNamara","year":"2020","journal-title":"Epilepsia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1212\/CON.0000000000000297","article-title":"Management of drug-resistant epilepsy","volume":"22","author":"Nair","year":"2016","journal-title":"Contin. (N Y)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10072-022-06393-1","article-title":"Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study","volume":"44","author":"Navarro","year":"2023","journal-title":"Neurol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.17533\/udea.iatreia.207","article-title":"Endocannabinoid system and the role of medical cannabis in treating spasticity: a narrative review","volume":"31","author":"Navarro","year":"2024","journal-title":"Iatreia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000541364","article-title":"Treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease with a cannabis-based magistral formulation: an open-label prospective cohort study","volume":"7","author":"Navarro","year":"2024","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100140","DOI":"10.1016\/j.lana.2021.100140","article-title":"Burden of epilepsy in Latin America and the Caribbean: a trend analysis of the global burden of disease study 1990-2019","volume":"8","author":"Pacheco-Barrios","year":"2022","journal-title":"Lancet Regional Health - Am."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/epi.16936","article-title":"The long\u2010term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/epi4.12376","article-title":"Is cannabidiol a drug acting on unconventional targets to control drug\u2010resistant epilepsy?","volume":"5","author":"Rocha","year":"2020","journal-title":"Epilepsia Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"106263","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.7399\/fh.11390","article-title":"Clinical pharmacology of cannabidiol in refractory epilepsy","volume":"44","author":"Schaiquevich","year":"2020","journal-title":"Farm. Hosp."},{"key":"B47","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.yebeh.2020.106949","article-title":"The global burden of epilepsy report: implications for low- and middle-income countries","volume":"105","author":"Singh","year":"2020","journal-title":"Epilepsy and Behav."},{"key":"B48","doi-asserted-by":"publisher","first-page":"107733","DOI":"10.1016\/j.neuropharm.2019.107733","article-title":"Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: pharmacodynamic and pharmacokinetic studies","volume":"158","author":"Soca\u0142a","year":"2019","journal-title":"Neuropharmacology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy and Behav."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in Tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/jcph.1387","article-title":"A review of human studies assessing cannabidiol\u2019s (CBD) therapeutic actions and potential","volume":"59","author":"White","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/ph14010035","article-title":"Comparison of five oral cannabidiol preparations in adult humans: pharmacokinetics, body composition, and heart rate variability","volume":"14","author":"Williams","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B54","first-page":"A07200527","article-title":"Cannabidiol treatment of severe refractory epilepsy in children and young adults","volume":"68","author":"Zilmer","year":"2021","journal-title":"Dan. Med. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1681815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:12:19Z","timestamp":1756959139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1681815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":54,"alternative-id":["10.3389\/fphar.2025.1681815"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1681815","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1681815"}}